Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.

Gaurav SyalGil Y MelmedChristopher V AlmarioBrennan M R Spiegel

Published in: Digestive diseases and sciences (2022)

Azathioprine withdrawal is the most effective and least costly de-escalation strategy in CD patients in remission on combination therapy if AZA re-introduction is performed upon CD relapse.

Keyphrases

combination therapy
end stage renal disease
ulcerative colitis
newly diagnosed
ejection fraction
disease activity
prognostic factors
randomized controlled trial
rheumatoid arthritis
clinical trial
systemic lupus erythematosus
patient reported
study protocol